

A case of chronic liver disease (hepatocellular carcinoma)

Ami Desai

October 16, 2019

Diagnostic Radiology, RAD 4001

Dr. Nathan Doyle & Dr. Sean Burke

Clinical History

- 70 y.o. female with obesity and known NASH cirrhosis (diagnosed 7 years ago) presenting with confusion and disorientation
- Current symptoms:
 - Mild confusion, disorientation, forgetfulness (increasing over past few months)
 - Lower extremity and abdominal swelling
- Physical exam findings:
 - Stable vitals: 98.0 F, HR: 78, RR: 16, BP: 141/82, SpO2: 95%
 - LE pitting edema 2+ bilaterally
 - Abdominal distension, no mention of shifting dullness
- Work-up (notable labs):
 - CBC with differential: low platelets (122,000 mm³)
 - Elevated alpha-fetoprotein (226 ng/mL) - *normal: 10-20 ng/mL*
 - >400 ng/mL is 95% specific for HCC¹

ACR Appropriateness Criteria

- Chronic liver disease: NASH; w/ symptoms of hepatic encephalopathy & notable labs
- Imaging was **appropriate** according to ACR appropriateness criteria²

Variant 2: Chronic liver disease. Screening and surveillance for hepatocellular carcinoma (HCC). No prior diagnosis of HCC.

Procedure	Appropriateness Category	Relative Radiation Level
MRI abdomen without and with IV contrast	Usually Appropriate	○
MRI abdomen without and with hepatobiliary contrast	Usually Appropriate	○
US abdomen	Usually Appropriate	○
CT abdomen with IV contrast multiphase	Usually Appropriate	☼☼☼☼
MRI abdomen without IV contrast	May Be Appropriate	○
MR elastography abdomen	May Be Appropriate	○
US elastography ARFI abdomen	May Be Appropriate	○
CT abdomen without IV contrast	Usually Not Appropriate	☼☼☼
FDG-PET/CT skull base to mid-thigh	Usually Not Appropriate	☼☼☼☼
1D transient elastography abdomen	Usually Not Appropriate	○
CT abdomen without and with IV contrast	Usually Not Appropriate	☼☼☼☼




Liver lesion in segment 3

- 9/30/19: Triple phase CT abdomen w/ and w/out contrast (liver protocol), axial views

Arterial phase:
hyperdense

Portal venous phase:
hyper-/isodense

Delayed phase:
hypodense



Label
Key

Yellow: 2.4x2.4x2.2cm mass in segment 6
Green: Portal vein (main branches)
Red: Stomach


Liver lesion in segment 6

- 9/30/19: Triple phase CT abdomen w/ and w/out contrast (liver protocol), axial views

Arterial phase:
hyperdense

Portal venous phase:
isodense

Delayed phase:
isodense



Label
Key


Yellow: 0.9x0.9x9.8cm mass in segment 6
Blue: calcified granulomas

Green: Portal vein
Red: Gastroduodenal junction

Additional liver findings

- 9/30/19: Triple phase CT abdomen w/ and w/out contrast (liver protocol); axial & coronal views

Portal venous phase



Label
Key


Nodular liver

Portal vein caliber = 1.6cm in this pt. (>13mm in diameter suggests portal HTN³)

Varices

- 9/30/19: Triple phase CT abdomen w/ and w/out contrast (liver protocol); axial views

Portal venous phase



Label
Key

Esophageal varices & gastric varices

Free fluid

- 9/30/19: Triple phase CT abdomen w/ and w/out contrast (liver protocol); axial view

Portal venous phase



Label
Key

Trace fluid adjacent to liver (possibly developing ascites)

Portal vein tumor thrombosis (*different patient*)



Coronal CT C&A, arterial phase



Coronal CT C&A, portal venous phase

Yellow arrow: Portal venous tumor thrombosis

Image Source URL: <https://radiopaedia.org/cases/infiltrative-hepatocellular-carcinoma-with-portal-vein-tumor-thrombosis?lang=us>

Summary of Key Imaging Findings

- Patient PMH: obesity, NASH (chronic liver disease)
- Patient CC: confusion, disorientation, forgetfulness, LE edema
- Imaging findings:
 - Multiple liver masses: one in segment 3 and one in segment 6
 - Calcified granulomas in right liver
 - Portal vein caliber of 1.6cm
 - Large esophageal & perigastric varices
 - Trace free fluid adjacent to the liver with mild mesenteric stranding

Differential Diagnosis: Hypervascular liver lesions

Hypervascular lesions	
Benign	Malignant
FNH	HCC
Adenoma	Hypervascular
Hemangioma	Metastases: Breast
	Sarcomas
	Neuroendocrine
	Renal Cell
	Melanoma

Figure 1⁵

- Liver has a dual blood supply: portal vein (80%) & hepatic artery (20%)
- Hemangiomas are the most common liver tumor⁶
- Cysts, abscesses, and certain types of metastasis (eg, from colon) are *hypovascular*, thus would *not* show this pattern of enhancement⁶

Discussion: LI-RADS Criteria (v2018)


Step 1: check if patient meets requirements to apply LI-RADS criteria for classification of liver masses

Use LI-RADS	Do not use LI-RADS
<ul style="list-style-type: none"> - Cirrhosis - Hep B +/- cirrhosis - Current or prior HCC 	<ul style="list-style-type: none"> - < 18 years - Cirrhosis in: <ul style="list-style-type: none"> - congenital hepatic fibrosis - Budd-Chiari - portal vein occlusion - diffuse nodular regenerative hyperplasia - cardiac congestion

Figure 2a⁷

Step 2: apply diagnostic algorithm to classify each liver mass

Arterial phase hyperenhancement (APHE)		No APHE		Nonrim APHE		
Observation size (mm)		< 20	≥ 20	< 10	10-19	≥ 20
Count additional major features: <ul style="list-style-type: none"> • Enhancing “capsule” • Nonperipheral “washout” • Threshold growth 	None	LR-3	LR-3	LR-3	LR-3	LR-4
	One	LR-3	LR-4	LR-4	LR-4 / LR-5	LR-5
	≥ Two	LR-4	LR-4	LR-4	LR-5	LR-5



Observations in this cell are categorized based on one additional major feature:

- LR-4 – if enhancing “capsule”
- LR-5 – if nonperipheral “washout” **OR** threshold growth

Figure 3a⁸

Discussion: LI-RADS Criteria (v2018) (cont.)

This patient:

- Segment 3 mass: 2.4x2.4x2.2cm, with non-peripheral washout
- Segment 6 mass: 0.9x0.9x9.8cm, with no additional major features





Major features	
	APHE Non-rim arterial phase hyperenhancement. Enhancement more than liverparenchyma in late arterial phase
	Non-peripheral washout Hypoenhancement in the extracellular phase <i>Extracellular phase = portal venous or delayed phase</i>
	Threshold growth Size increase of 50% or more within 6 months time.
	Capsule Smooth, uniform border surrounding all or most of an observation. Usually thicker than fibrotic tissue surrounding nodules. Enhancement in portal venous, delayed or transitional phase.

Figure 2b⁷

Discussion: LI-RADS Criteria (v2018) (cont.)

Step 3: determine next steps after classifying each liver mass




Figure 3b⁸

Final Diagnosis: Hepatocellular carcinoma

- Most likely secondary to NASH
- HCC can be solitary, multiple masses, or diffusely infiltrating⁶
- LI-RADS criteria for **hepatocellular carcinoma**:
 - Segment 3 mass meets LI-RADS grade 5 (diagnostic of HCC)
 - Segment 6 mass meets LI-RADS grade 3

Treatment Options: TACE

- Patient has been referred to IR for **TACE procedure**, and is also awaiting a liver transplant
- **Transcatheter Arterial Chemoembolization (TACE)**: administration of chemoembolic microspheres directly into main arterial branch supplying tumor

Other Treatment Options

- Minimally invasive treatments:
 - Thermal ablation (limitations⁹: size >5cm, near major vessels, # of nodules ≥ 3)
 - Transcatheter Arterial Chemoembolization (TACE)
 - Transarterial Y90 Radioembolization
- Other treatments:
 - Liver resection
 - Liver transplant (*this patient*: MELD score: 11; Karnofsky score: 60)
 - Systemic chemotherapeutic agents (sorafenib, regorafenib)

Cost of Imaging at Memorial Hermann

- CT Abdomen W/ & W/O Contrast¹⁰
 - Insured: charged \$6,534, patient owes \$284
 - Uninsured: patient owes \$2,352

Take Home Points

- Hypervascular liver lesions *enhance* in arterial phase, whereas normal liver parenchyma will not enhance until portal venous phase
- LI-RADS grade 5 on CT or MRI is diagnostic of hepatocellular carcinoma
- Consider minimally invasive procedures (thermal ablation, TACE, Y90 radioembolization) to treat patients with HCC who meet criteria

References

- (1) Chan SL, Mo F, Johnson PJ, et al. Performance of serum α -fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. *HPB (Oxford)*. 2014;16(4):366-72.
- (2) ACR Appropriateness Criteria, Chronic Liver Disease. Website URL: <https://acsearch.acr.org/docs/3098416/Narrative/>
- (3) Bogdan Procopet, Annalisa Berzigotti, Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy, *Gastroenterology Report*, Volume 5, Issue 2, May 2017, Pages 79–89, <https://doi.org/10.1093/gastro/gox012>
- (4) Portal Vein Tumor Thrombosis. Website URL: <https://radiopaedia.org/cases/infiltrative-hepatocellular-carcinoma-with-portal-vein-tumor-thrombosis?lang=us>
- (5) Hypervascular lesions. Website URL: https://radiologyassistant.nl/assets/liver-masses-i-characterisation/a509797744c753_TAB-hypervascular.png
- (6) Herring, W. (2007). *Learning Radiology: Recognizing the Basics*. 4th ed. Philadelphia: Elsevier, pp.181-183.
- (7) Liver – LI-RADS, Major Features. Website URL: <https://radiologyassistant.nl/abdomen/liver-segmental-anatomy-1>
- (8) American College of Radiology, LI-RADS Criteria v2018. CT/MRI Diagnostic Table. Website URL: <https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LI-RADS-2018-Core.pdf?la=en>
- (9) Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. *Cardiovasc Intervent Radiol*. 2010;33(1):11–17. doi:10.1007/s00270-009-9736-y
- (10) Cost of Imaging at Memorial Hermann. Website URL: <https://www.memorialhermann.org/patients-caregivers/pricing-estimates-and-information/>



Questions?